The first-in-human, randomised, double-blind, placebo-controlled Phase I trial of the company’s orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), DC-806 has been designed to generate safety and pharmacokinetic data.
It will also provide early clinical proof-of-concept in patients living with skin disease psoriasis.
The trial is being carried out in three overlapping parts that include Phase Ia (single ascending dose) and Phase Ib (multiple ascending dose) in healthy subjects.
A Phase Ic (proof-of-concept) part of the trial will be conducted in psoriasis patients.
Dice Therapeutics CEO Kevin Judice said: “Completion of enrollment in the Phase I study of DC-806 is an important step towards our objective of providing transformative oral medicines to patients suffering from psoriasis and other chronic autoimmune and inflammatory disorders.
“IL-17 is a validated and powerful driver of psoriasis and we believe this ongoing Phase I study will provide us with early safety and proof-of-concept data, as well as dose selection guidance for future studies.”
The company expects topline proof-of-concept data in healthy volunteers as well as psoriasis patients in the second half of this year.
The therapeutic candidates in the oral IL-17 franchise of Dice are being developed initially to treat psoriasis.
According to research over the past 20 years, IL-17 is a driver of the psoriasis that manifests as erythematous plaques with thick scaling that can occur on any part on the body.